Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

INTRODUCTION: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Rheumatol Ther
Hlavní autoři: Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://ncbi.nlm.nih.gov/pubmed/31721017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00182-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky